Solms A., Shah A., Berntorp E., Tiede A., Iorio A., Linardi C., Ahsman M., Mancuso M. E., Zhivkov T., Lissitchkov T. Direct comparison of two extended half-life PEGylated recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Ann. Hematol. 99(11): 2689–2698, 2020 [Link to publication].
Shah A., Solms A., Wiegmann S., Ahsman M., Berntorp E., Tiede A., Iorio A., Mancuso M.E., Zhivkov T., Lissitchkov T. Direct comparison of two extended-half-life recombinant FVIII products: a randomized, crossover pharmacokinetic study in patients with severe hemophilia A. Annals of Hematology: 2035-2044, 2019. [Link to publication]
Solms A., Iorio A., Ahsman M. J., Vis P., Shah A., Berntorp E., Garmann D. Favorable Pharmacokinetic Characteristics of Extended ‑ Half ‑ Life Recombinant Factor VIII BAY 94 ‑ 9027 Enable Robust Individual Profiling Using a Population Pharmacokinetic Approach. Clin. Pharmacokinet, 2019. [Link to publication]
Garmann D., McLeay S., Shah A., Vis P., Maas Enriquez M., Ploeger, B.A. Population pharmacokinetic characterization of BAY 81-8973, a full-length recombinant factor VIII: lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit. Haemophilia: 528–537, 2017. [Link to publication]
Recombinant Antithrombin (ATryn) to achieve >80% AT activity in pediatric and neonatal ECMO patients
DeJongh J., Streisand J., Todd Tzanetos D., Fanning J. and Drenth H., Recombinant Antithrombin (ATryn) to achieve >80% AT activity in pediatric and neonatal ECMO patients. 26th Annual ELSO Conference.(2015) [Link to publication]
Paidas M.J., Frieling J., de Jongh J., Drenth H.J. and Streisand J., Dose Selection of Antithrombin (Recombinant) for a Phase 3 Trial in Early-Onset Preeclampsia [149], Obstet Gynecol., 125(Suppl 1): 52S., 2015. [Link to publication]
DeJongh J., Frieling J., Lowry S., Drenth H. and Finch M., Development of a dosing regimen for recombinant human antithrombin (rhAT) in pregnant patients. 60th Annual Meeting of the Society for Gynecologic Investigation (SGI) (2013) [Link to publication]
Dejongh J., Frieling J., Lowry S. and Drenth H.J., Pharmacokinetics of Recombinant Human Antithrombin in Delivery and Surgery Patients With Hereditary Antithrombin Deficiency, Clin Appl Thromb Hemost, 11: 11, 2013. [Link to publication]
Stringer F., Ploeger B., Scott G., Kawamura M. and Kupfer S., Pharmacokinetic and pharmacodynamic modeling of the novel oral direct factor Xa inhibitor TAK-442. ASCPT (2009).
- « Previous
- 1
- 2